
INCR Valuation
InterCure Ltd
INCR Relative Valuation
INCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INCR is overvalued; if below, it's undervalued.
Historical Valuation
InterCure Ltd (INCR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4.56 is considered Overvalued compared with the five-year average of -0.38. The fair price of InterCure Ltd (INCR) is between 0.80 to 1.34 according to relative valuation methord. Compared to the current price of 1.40 USD , InterCure Ltd is Overvalued By 4.8%.
Relative Value
Fair Zone
0.80-1.34
Current Price:1.40
4.8%
Overvalued
0.00
PE
1Y
3Y
5Y
Trailing
Forward
1.15
EV/EBITDA
InterCure Ltd. (INCR) has a current EV/EBITDA of 1.15. The 5-year average EV/EBITDA is 0.28. The thresholds are as follows: Strongly Undervalued below -24.26, Undervalued between -24.26 and -11.99, Fairly Valued between 12.55 and -11.99, Overvalued between 12.55 and 24.82, and Strongly Overvalued above 24.82. The current Forward EV/EBITDA of 1.15 falls within the Historic Trend Line -Fairly Valued range.
1.28
EV/EBIT
InterCure Ltd. (INCR) has a current EV/EBIT of 1.28. The 5-year average EV/EBIT is -7.90. The thresholds are as follows: Strongly Undervalued below -106.97, Undervalued between -106.97 and -57.44, Fairly Valued between 41.64 and -57.44, Overvalued between 41.64 and 91.18, and Strongly Overvalued above 91.18. The current Forward EV/EBIT of 1.28 falls within the Historic Trend Line -Fairly Valued range.
4.56
PS
InterCure Ltd. (INCR) has a current PS of 4.56. The 5-year average PS is 1.46. The thresholds are as follows: Strongly Undervalued below -0.72, Undervalued between -0.72 and 0.37, Fairly Valued between 2.55 and 0.37, Overvalued between 2.55 and 3.64, and Strongly Overvalued above 3.64. The current Forward PS of 4.56 falls within the Strongly Overvalued range.
0.00
P/OCF
InterCure Ltd. (INCR) has a current P/OCF of 0.00. The 5-year average P/OCF is 5.38. The thresholds are as follows: Strongly Undervalued below -17.56, Undervalued between -17.56 and -6.09, Fairly Valued between 16.86 and -6.09, Overvalued between 16.86 and 28.33, and Strongly Overvalued above 28.33. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
InterCure Ltd. (INCR) has a current P/FCF of 0.00. The 5-year average P/FCF is 37.37. The thresholds are as follows: Strongly Undervalued below -285.33, Undervalued between -285.33 and -123.98, Fairly Valued between 198.72 and -123.98, Overvalued between 198.72 and 360.07, and Strongly Overvalued above 360.07. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
InterCure Ltd (INCR) has a current Price-to-Book (P/B) ratio of 0.60. Compared to its 3-year average P/B ratio of 0.73 , the current P/B ratio is approximately -18.00% higher. Relative to its 5-year average P/B ratio of 1.33, the current P/B ratio is about -54.93% higher. InterCure Ltd (INCR) has a Forward Free Cash Flow (FCF) yield of approximately -7.36%. Compared to its 3-year average FCF yield of -6.01%, the current FCF yield is approximately 22.31% lower. Relative to its 5-year average FCF yield of -3.62% , the current FCF yield is about 103.12% lower.
0.60
P/B
Median3y
0.73
Median5y
1.33
-7.36
FCF Yield
Median3y
-6.01
Median5y
-3.62
Competitors Valuation Multiple
The average P/S ratio for INCR's competitors is 10.07, providing a benchmark for relative valuation. InterCure Ltd Corp (INCR) exhibits a P/S ratio of 4.56, which is -54.68% above the industry average. Given its robust revenue growth of 7.52%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of INCR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of INCR in the past 1 year is driven by Unknown.
People Also Watch

CTM
Castellum Inc
1.170
USD
+13.59%

GALT
Galectin Therapeutics Inc
5.810
USD
+14.60%

PBHC
Pathfinder Bancorp Inc (MARYLAND)
15.020
USD
-0.53%

OKUR
Onkure Therapeutics Inc
3.390
USD
+1.19%

ANIX
Anixa Biosciences Inc
4.130
USD
+1.72%

EPIX
ESSA Pharma Inc
0
USD
-1.99%

CATO
Cato Corp
3.850
USD
+4.62%

IPSC
Century Therapeutics Inc
0.583
USD
-1.52%

LSBK
Lake Shore Bancorp Inc
13.820
USD
-0.29%
FAQ
Is InterCure Ltd (INCR) currently overvalued or undervalued?
InterCure Ltd (INCR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4.56 is considered Overvalued compared with the five-year average of -0.38. The fair price of InterCure Ltd (INCR) is between 0.80 to 1.34 according to relative valuation methord. Compared to the current price of 1.40 USD , InterCure Ltd is Overvalued By 4.80% .








